top of page

Vantrela ER

  HCP LAUNCH CAMPAIGN 

This HCP launch campaign’s goal was to own the transition from short-acting hydrocodone products to long-acting opioid. As well as differentiate VANTRELA ER from other long-acting opioids based on product attributes. VANTRELA ER is intelligently designed to make a real difference in the life of chronic pain patients.Treating patients with a long-acting opioid gives them the pain relief that enables them to re-engage in life. Yet, not  all ER opioids are built with the patients’ needs in mind. Vantrela ER is designed for relief.

Last updated June 2023

bottom of page